Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Mount Sinai Hospital
1468 Madison AvenueAnnenberg Building, 4th Floor
New York, New York, United States
Phone Web
In addition to dedicated treatment programs in hemophilia, sickle cell disease, and thrombophilia, our physicians provide care to children with anemia secondary to hemoglobinopathy, red cell membrane or enzyme disorders, aplastic anemia (including Fanconi’s anemia), thrombocytopenia (also known as ITP), neutropenia, polycythemia, and thrombocytosis.
Hematological conditions treated here include:
-Sickle cell disease
-Hemoglobinopathies
-Anemia
-Congenital and acquired thrombocytopenia including ITP
-Bleeding and clotting disorders
Our pediatric hematologists have been delivering state-of-the-art care to all patients with sickle cell disease for several decades. Basic research at Mount Sinai has included gene therapy for hemoglobinopathy, studies on cell interactions that lead to the excessive adhesion of red cells and enhancement of fetal hemoglobin to minimize the symptoms of sickle cell disease. The Sickle Cell Program here is a comprehensive program designed to provide holistic care. Patients have access to social workers, genetic counselors, cardiologists, pulmonologists, neurologists, and psychologists. Together with the experienced Pediatric Intensive Care Unit staff, the hospital treats the most life threatening complications such as stroke and acute chest syndrome. The blood bank provides accessibility to hemopheresis for emergencies.
+myBinderRelated Content
-
Association Between Hospital Admissions and Healthcare Provider Communication for Individuals With Sickle Cell Disea...Objective: To test the hypothesis that ...
-
Kathryn Hassell, MDDr. Hassell provides inpatient and outpa...
-
Barbara Yawn, MDBarbara P. Yawn, MD, MSc, FAAFP, is Adju...
-
NYC Health + HospitalsNYC Health + Hospitals are the largest p...
-
Healthcare Providers and Sickle Cell DiseaseSickle cell disease (SCD) is a group of ...
-
@juliemakaniScientist|Doctor - Sickle Cell Disease f...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
